A carregar...

State-of-the-art pharmacological approaches to reduce chorea in Huntington’s Disease

INTRODUCTION: Chorea is a common motor manifestation of Huntington’s disease (HD). Two vesicular monoamine transporter type 2 (VMAT-2) inhibitors have been approved by the FDA for treatment of HD chorea, and a third is currently being assessed in a phase 3 trial. Antipsychotic therapies are used off...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Expert Opin Pharmacother
Main Authors: Gibson, Jessie S., Claassen, Daniel O.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8222076/
https://ncbi.nlm.nih.gov/pubmed/33550875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14656566.2021.1876666
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!